Fig. 2From: The perfect personalized cancer therapy: cancer vaccines against neoantigensPersonalized NCV in the context of current immunotherapy, the three dimensions are defined by tumor infiltrating lymphocytes (TILs), mutational load (ML) and tumor heterogeneity (TH). Patients in the lower right panel (TIL−ML+TH+) may benefit from Neoantigen cancer vaccine (NCV) approach whereas patients in the upper right panel (TILs+ML+TH−) respond more to immune checkpoint inhibitors (ICI)Back to article page